This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Infirst HEALTHCARE To Commercialise Novel Consumer Healthcare Drugs

LONDON, March 25, 2013 /PRNewswire/ --

£25 Million Fundraising for Fast-to-Market Medicines

infirst HEALTHCARE, the consumer healthcare company commercialising unique, fast-to-market consumer medicines, today announces it has successfully raised £25 million of new funds. The funding, from Invesco Asset Management managed funds, will be used for the launch of the company's medicines into the US$20 billion cough & cold and pain consumer healthcare markets where there has been little innovation for decades.

The company's fast-to-market portfolio utilizes infirst ' s intellectual property which centres on improving the profile of safe and well-established drugs. The first products to be launched will be in the cough & cold and pain indications. These represent the most prevalent symptomatic health conditions at the primary care level and the two largest segments of the global OTC market.

infirst HEALTHCARE is led by Manfred Scheske, who was President of GlaxoSmithKline's US$3 billion European Consumer Healthcare business until 2010, overseeing and launching some of the largest consumer healthcare brands in the industry. infirst ' s management team also includes Andrew Waters as Chief Financial Officer, a PwC qualified accountant who held senior finance roles with GlaxoSmithKline Consumer Healthcare & Pharma for 16 years. Infirst's Board will be chaired by former Rothschild investment banker, Dr Lynn Drummond, who has a strong track record in the healthcare sector bringing over 20 years of management and advisory experience. Also on infirst ' s Board will be Gregory Stoloff (CEO and founder of SEEK Group, from which infirst HEALTHCARE has been spun out) and Kimbell Duncan (who has over 25 years experience as investment banker and investor).

Infirst has developed a strong portfolio of pipeline products. Its strategic focus - ' Known drugs  -  made better ' - unlocks opportunities which permit rapid product development, swift pathways to regulatory approval and IP protection.

Infirst will launch its first product, a cocoa-flavoured cough liquid, in Europe. The company is also developing a non-narcotic/non-opioid cough treatment which is in a Phase III clinical study, targeted for a 2015 market launch. The North American rights to infirst ' s cough related IP have been out-licensed to NASDAQ listed US company Pernix Therapeutics Holdings, Inc.  infirst is also developing an ibuprofen-based product for the treatment of inflammatory pain, to which it has the global rights.

Commenting on today's announcement, Manfred Scheske, CEO of infirst HEALTHCARE, said:

"Cough & cold and pain are the largest and most prevalent conditions in the consumer health sector and represent an enormous opportunity for infirst to bring innovation and efficacy to a market which has seen very few new products and only marginal innovation for decades. We are delighted that Invesco has become a major shareholder in our company and we look forward to delivering value for all of our shareholders in the coming years."

About  infirst    HEALTHCARE

infirst HEALTHCARE is a new consumer healthcare company focused on improving well established  drugs with IP protected solutions for the OTC/Primary care markets which can be launched within 12-36 months. infirst is a spin-out from SEEK, a UK privately-owned drug discovery group which uses its intellectual property to create breakthrough medicines addressing major diseases, bringing radical improvements to human health.

infirst is led by CEO, Manfred Scheske, who  was previously President of GSK's US$3 billion European Consumer Healthcare business (including brands such as alli, Aquafresh, Beechams, Corsodyl, Lucozade, Niquitin, Panadol. Piriton, Poligrip, Ribena, Sensodyne, Solpadeine, Zantac and Zovirax) from 2004 to 2010 and also spent six years as President of GSK's Consumer Healthcare business in North America.

About SEEK

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs